Compare CCC & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCC | CPRX |
|---|---|---|
| Founded | 1980 | 2002 |
| Country | United States | United States |
| Employees | 2185 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.4B |
| IPO Year | N/A | 2006 |
| Metric | CCC | CPRX |
|---|---|---|
| Price | $5.31 | $28.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $8.94 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 11.6M | 1.8M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 1.68 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | $10.22 | $9.20 |
| Revenue Next Year | $8.58 | $10.51 |
| P/E Ratio | ★ N/A | $17.18 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $4.58 | $19.05 |
| 52 Week High | $8.68 | $32.56 |
| Indicator | CCC | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 66.77 |
| Support Level | $4.86 | $22.41 |
| Resistance Level | $6.34 | $32.56 |
| Average True Range (ATR) | 0.29 | 1.19 |
| MACD | 0.02 | 0.19 |
| Stochastic Oscillator | 58.66 | 48.07 |
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies, and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, AI-enabled digital workflows. It operates in a single segment being Domestic segment, which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in the United States and China. The majority of the revenue is generated from the United States.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.